Cebaracetam
Appearance
Clinical data | |
---|---|
Other names | CGS-25248; ZY-15119 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18ClN3O3 |
Molar mass | 335.79 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Cebaracetam (INN ; developmental code names CGS-25248; ZY-15119) is an experimental drug of the racetam group described as a nootropic which was never marketed.[1][2][3]
It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and is also a derivative of RGPU-95 (4-chlorophenylpiracetam).[4] It is the analogue of RGPU-95 in which the terminal amide group has been replaced with a piperazin-2-one moiety.[4] The mechanism of action of cebaracetam is undefined or unknown.[1]
The drug was under development by Novartis for the treatment of cognition disorders by the 1990s but development was discontinued in 1995.[1] It reached phase 2 clinical trials prior to its discontinuation.[1]
References
[edit]- ^ a b c d "Cebaracetam". AdisInsight. 23 May 1995. Retrieved 1 October 2024.
- ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/stembook-2018.pdf
- ^ Chollet D, Künstner P (June 1992). "Fast systematic approach for the determination of drugs in biological fluids by fully automated high-performance liquid chromatography with on-line solid-phase extraction and automated cartridge exchange. Application to cebaracetam in human urine". Journal of Chromatography. 577 (2): 335–340. doi:10.1016/0378-4347(92)80255-o. PMID 1400764.
- ^ a b "Cebaracetam". PubChem. Retrieved 1 October 2024.